Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study
MT Wang, JT Liou, CW Lin, CL Tsai… - JAMA Internal …, 2018 - jamanetwork.com
Importance The associations between cardiovascular disease (CVD) and inhaled long-
acting β 2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic …
acting β 2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic …
Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease
A Gershon, R Croxford, A Calzavara, T To… - JAMA internal …, 2013 - jamanetwork.com
Importance Chronic obstructive pulmonary disease (COPD) is a common and deadly
disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for …
disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for …
Chronic obstructive pulmonary disease exacerbations and pneumonia hospitalizations among new users of combination maintenance inhalers
Importance Clinical guidelines on chronic obstructive pulmonary disease (COPD)
recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long …
recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long …
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
P Rogliani, MG Matera, J Ora, M Cazzola… - International journal of …, 2017 - Taylor & Francis
Objective Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled …
CV Asche, S Leader, C Plauschinat… - … journal of chronic …, 2012 - Taylor & Francis
Background To estimate the potential cost savings by following the current Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being …
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being …
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease
ML Decramer, NA Hanania, JO Lötvall… - International journal of …, 2013 - Taylor & Francis
Background Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for
chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β2 …
chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β2 …
Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study
Background Long-acting bronchodilators, including long-acting beta 2-agonists (LABA) and
the anticholinergic tiotropium, are recommended as initial maintenance therapy in COPD …
the anticholinergic tiotropium, are recommended as initial maintenance therapy in COPD …
β-Blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. An observational …
MT Dransfield, DA McAllister, JA Anderson… - Annals of the …, 2018 - atsjournals.org
Rationale: Cardiovascular disease is a common comorbidity in patients with chronic
obstructive pulmonary disease. Although β-blockers can be used safely in patients with …
obstructive pulmonary disease. Although β-blockers can be used safely in patients with …
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis
Background: Most patients with moderate and severe chronic obstructive pulmonary disease
(COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however …
(COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however …